|  |  |  |
| --- | --- | --- |
| **DRUG, SPONSOR** | **DRUG TYPE OR USE** | **PBAC OUTCOME** |
| ECULIZUMAB  300 mg/30 mL injection, 1 x 30mL vial    Soliris®    Alexion Pharmaceuticals Australasia Pty Ltd | Atypical Haemolytic Uraemic Syndrome (aHUS) | The PBAC noted that the sponsor of eculizumab, Alexion Pharmaceuticals, had been requested by the Department to provide updated data regarding the use of eculizumab in the context of renal transplant. A submission subsequently provided by the sponsor included a significant volume of new data that have reached the public domain since the PBAC’s August 2014 recommendation to list eculizumab on the PBS. The PBAC noted that some new data had not been previously submitted for the Committee’s consideration, nor had they been formally evaluated. The PBAC noted that the submission had been referred for evaluation and that it would be considered as part of the March 2016 agenda. |